SCHEMBL24387441

SCHEMBL24387441

OC1CCc2cc(Cl)cc(Cl)c21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 5/20 0.39
ALDH1A1 P00352 5/20 0.34
TSHR P16473 3/20 0.34
HSD17B10 Q99714 3/20 0.34
CYP3A4 P08684 2/20 0.34
RECQL P46063 2/20 0.34
MAP3K14 Q99558 1/20 0.33
HPGD P15428 3/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
SLC22A2 O15244 1/20 0.32
SLC22A1 O15245 1/20 0.32
NR1I2 O75469 1/20 0.32
SLC22A3 O75751 1/20 0.32
EGFR P00533 1/20 0.32
LMNA P02545 1/20 0.32
TTR P02766 1/20 0.32
ESR1 P03372 1/20 0.32
ERBB2 P04626 1/20 0.32
LCK P06239 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30686715 1.00 P2RX7 (0.39) P2RX7ALDH1A1TSHRHSD17B10CYP3A4
SCHEMBL31285321 0.85 FNTA (0.32) P2RX7MAP3K14
SCHEMBL30049095 0.81 HTT (0.33) HTT
SCHEMBL18204532 0.81 HPGD (0.35) HPGDEPAS1CYP11B1CYP11B2
SCHEMBL29181820 0.81 HTT (0.33) HTT
SCHEMBL15129214 0.76 P2RX7 (0.36) P2RX7ALDH1A1SLC6A2DRD3SLC6A3
SCHEMBL15129304 0.76 P2RX7 (0.36) P2RX7ALDH1A1SLC6A2DRD3SLC6A3
SCHEMBL15129202 0.76 P2RX7 (0.36) P2RX7ALDH1A1SLC6A2DRD3SLC6A3
SCHEMBL15129213 0.74 P2RX7 (0.47) P2RX7ALDH1A1HPGD
SCHEMBL15129452 0.74 P2RX7 (0.47) P2RX7ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230381132-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2023-11-30 US disclosed
US-20230381132-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2023-11-30 US disclosed
US-20230381132-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2023-11-30 US disclosed
EP-4237402-A1 NOVEL COMPOUNDS Sitryx Therapeutics Limited (GB) 2023-09-06 EP disclosed
WO-2022090714-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2022-05-05 WO disclosed
WO-2022090714-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2022-05-05 WO disclosed
CN-103097364-B Spiro-piperidine derivatives as S1P modulators ABBOTT HEALTHCARE PRODUCTS B.V. (NL) 2015-11-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230381132-A1 NOVEL COMPOUNDS CNKSR1, RORC, RCOR3 P2RX7 2001/4885ALDH1A1 311/4885TSHR 1974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.